Overview
Fungal infections pose a significant global health burden, ranging from superficial skin conditions to life-threatening systemic mycoses, particularly in immunocompromised individuals. Accurate identification of the causative fungal species is critical for effective treatment, as different species exhibit varying susceptibilities to antifungal agents. Traditional diagnostic methods, such as culture and microscopy, often lack sensitivity and may fail to distinguish closely related species. Fungal Genome De Novo Assembly and Annotation using Illumina technology offers a comprehensive solution by sequencing the entire fungal genome, assembling the DNA fragments into a complete genome, and annotating the genes to understand their functions. This advanced genomic approach enables precise species identification, detection of virulence factors, and prediction of antifungal resistance markers. DNA Labs India provides this state-of-the-art service at a cost of INR 20,000, facilitating accurate diagnosis and guiding personalized therapeutic strategies. The process involves high-throughput sequencing, robust bioinformatics pipelines, and expert interpretation, ensuring reliable results for clinicians and researchers.
To be completed — reclassified from Tests on 2026-11-13.
The primary purpose of Fungal Genome De Novo Assembly and Annotation is to determine the complete genetic sequence of a fungal pathogen from a clinical sample. This allows for: 1) Definitive species identification, even for rare or non-culturable fungi. 2) Characterization of genetic elements associated with pathogenicity and drug resistance. 3) Phylogenetic analysis to understand transmission and outbreaks. 4) Discovery of novel genes and metabolic pathways. 5) Support for epidemiological surveillance and public health interventions. By providing a whole-genome view, this test surpasses targeted PCR or Sanger sequencing in resolution and comprehensiveness, making it invaluable for complex or treatment-refractory infections.
Sample requirements
What to send us
Deliverables & turnaround
What you receive
Turnaround: Results are typically available within 4 weeks after the sample reaches the laboratory.
Pricing
Transparent pricing
| Option | Turnaround | Price (INR) | Unit |
|---|---|---|---|
| Standard | Results are typically available within 4... | ₹20,000 | per sample |
Limitations & precautions
What this service cannot do
Questions customers ask
Frequently asked questions
What is the cost of Fungal Genome De Novo Assembly and Annotation?
The cost is INR 20,000, which includes sample collection, sequencing, and bioinformatics analysis.
What sample types are accepted for this test?
We accept tissue biopsies, body fluids, culture isolates, and other clinical specimens. Please contact us for specific sample requirements.
How long does it take to get results?
Results are typically available within 4 weeks after the sample is received in the laboratory.
Is home sample collection available?
Yes, we offer free home sample collection for online bookings across major cities in India.
What is the difference between de novo assembly and re-sequencing?
De novo assembly constructs a new genome without a reference, while re-sequencing maps reads to a known reference. De novo is essential for novel or poorly characterized fungi.
Can this test detect antifungal resistance?
Yes, the annotation includes identification of known resistance genes and mutations, aiding in treatment decisions.
Is this test covered by insurance?
Currently, this test is not covered by most insurance schemes. However, you may check with your provider for possible reimbursement.
What is the turnaround time for the report?
The turnaround time is 4 weeks from sample receipt.
Do I need to fast before the test?
No, fasting is not required for this test.
Can this test be performed on a blood sample?
Blood is not typically used for fungal genome sequencing; tissue or fluid from the infection site is preferred.
How accurate is the species identification?
Whole genome sequencing provides the highest resolution for species identification, with accuracy exceeding 99% when sufficient DNA is available.
Are there any risks associated with sample collection?
Risks are minimal and include slight bleeding or infection at the biopsy site. These are rare and managed by healthcare professionals.
Continue here
Related services
Enquiry
Request a quote or ask a question
Editorial accountability